The UK's SkyePharma reported a higher annual loss, but added that it expects to sign on a major partner for its asthma drug Flutiform. Flutiform went into Phase III in February. It's one of a new class of combination drugs and the brightest prospect in SkyePharma's pipeline. SkyePharma executives say that no other drug like it will hit the market for another six years.
- read the BBC report